Drug-induced renal calculi;Lithiases médicamenteuses

Annales d'Urologie

Volumn 40, Issue 2, 2006, Pages 57-68

  Servais, A ^a   Daudon, M ^a   Knebelman, B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Drug induced renal calculi; Indinavir; Metabolic calculi; Sulfadiazine; Triamterene

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOPENICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; CALCIUM; CARBONATE DEHYDRATASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; CORTICOSTEROID; EPHEDRINE; FOSCARNET; GUAIFENESIN; INDINAVIR; LAXATIVE; NAFTIDROFURYL OXALATE; NELFINAVIR; NIMESULIDE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SILICATE; SULFADIAZINE; SULFONAMIDE; UNINDEXED DRUG; URICOSURIC AGENT; VITAMIN D;

CRYSTALLIZATION; CRYSTALLURIA; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG EFFECT; DRUG EXCRETION; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG URINE LEVEL; HUMAN; HYPERCALCIURIA; INFRARED SPECTROSCOPY; KIDNEY FAILURE; METABOLISM; NEPHROLITHIASIS; PRESCRIPTION; PREVALENCE; RISK FACTOR; SHORT SURVEY; STONE ANALYSIS; URINE PH; URINE VOLUME; VITAMIN SUPPLEMENTATION; X RAY DIFFRACTION;

HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY CALCULI;

EID: 33646051540     PISSN: 00034401     EISSN: 17683378     Source Type: Journal    
DOI: 10.1016/j.anuro.2006.01.002     Document Type: Short Survey

References (75)

1. Ettinger B., Oldroyd N.O., and Sorgel F. Triamterene nephrolithiasis. JAMA 244 (1980) 2443-2445
2. Asper R., and Schmucki O. Critical aspects of urine and stone analysis. Appearance of iatrogenic urinary calculi. Urol. Int. 41 (1986) 334-342
3. Rapado A., Traba M.L., Caycho C., and Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib. Nephrol. 58 (1987) 25-29
4. Reveillaud R.J., and Daudon M. Drug-induced urinary lithiasis. Presse Med. 12 (1983) 2389-2392
5. Daudon M., and Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 64 (2004) 245-275
6. Boubaker K., Sudre P., Bally F., Vogel G., Meuwly J.Y., Glauser M.P., et al. Changes in renal function associated with indinavir. AIDS 12 (1998) F249-F254
7. Reiter W.J., Schon-Pernerstorfer H., Dorfinger K., Hofbauer J., and Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J. Urol. 161 (1999) 1082-1084
8. Saltel E., Angel J.B., Futter N.G., Walsh W.G., O'Rourke K., and Mahoney J.E. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J. Urol. 164 (2000) 1895-1897
9. Hermans B.P., Materne R., Marot J.C., Vandercam B., Van Beers B.E., and Van Cangh P.J. Indinavir calculi: diagnosis with magnetic resonance urography. Eur. Urol. 37 (2000) 634-635
10. Kopp J.B., Miller K.D., Mican J.A., Feuerstein I.M., Vaughan E., Baker C., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 127 (1997) 119-125
11. Hermieu J., Prevot M., Ravery V., Sauty L., Moulinier F., Delmas V., et al. Urolithiasis and the protease inhibitor indinavir. Eur. Urol. 35 (1999) 239-241
12. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Meibohm A., Condra J.H., et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133 (2000) 35-39
13. Gentle D.L., Stoller M.L., Jarrett T.W., Ward J.F., Geib K.S., and Wood A.F. Protease inhibitor-induced urolithiasis. Urology 50 (1997) 508-511
14. Sundaram C.P., and Saltzman B. Urolithiasis associated with protease inhibitors. J. Endourol. 13 (1999) 309-312
15. Kohan A.D., Armenakas N.A., and Fracchia J.A. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J. Urol. 161 (1999) 1765-1768
16. Blake S.P., Mc Nicholas M.M., and Raptopoulos V. Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. AJR Am. J. Roentgenol. 171 (1998) 717-720
17. Schwartz B.F., Schenkman N., Armenakas N.A., and Stoller M.L. Imaging characteristics of indinavir calculi. J. Urol. 161 (1999) 1085-1087
18. Van Glabeke E., Conort P., Chartier-Kastler E., Desrez G., Boyer C., and Richard F. Treatment of complicated renal colic in patients treated with indinavir: value of double J stents. Prog. Urol. 9 (1999) 470-473
19. Martinez E., Leguizamon M., Mallolas J., Miro J.M., and Gatell J.M. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin. Infect. Dis. 29 (1999) 422-425
20. Bach M.C., and Godofsky E.W. Indinavir nephrolithiasis in warm climates. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14 (1997) 296-297
21. Tashima K.T., Horowitz J.D., and Rosen S. Indinavir nephropathy. N. Engl. J. Med. 336 (1997) 138-140
22. van Rossum A.M., Dieleman J.P., Fraaij P.L., Cransberg K., Hartwig N.G., Gyssens I.C., et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS 15 (2001) 1745-1747
23. Berns J.S., Cohen R.M., Silverman M., and Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am. J. Kidney Dis. 30 (1997) 558-560
24. Martinez F., Mommeja-Marin H., Estepa-Maurice L., Beaufils H., Bochet M., Daudon M., et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol. Dial. Transplant. 13 (1998) 750-753
25. Sarcletti M., Petter A., Romani N., Lhotta K., Konig P., Maier H., et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin. Nephrol. 54 (2000) 261-270
26. Perazella M.A., Kashgarian M., and Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin. Nephrol. 50 (1998) 194-196
27. Daudon M., Estepa L., Viard J.P., Joly D., and Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 349 (1997) 1294-1295
28. Yeh K.C., Deutsch P.J., Haddix H., Hesney M., Hoagland V., Ju W.D., et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42 (1998) 332-338
29. Engeler D.S., John H., Rentsch K.M., Ruef C., Oertle D., and Suter S. Nelfinavir urinary stones. J. Urol. 167 (2002) 1384-1385
30. Maurice-Estepa L., Daudon M., Katlama C., Jouanneau C., Sazdovitch V., Lacour B., et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am. J. Kidney Dis. 32 (1998) 392-400
31. Trolliet P., Dijoud F., Cotte L., Cahen R., Francois B., Trepo C., et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am. J. Nephrol. 15 (1995) 256-259
32. Sawyer M.H., Webb D.E., Balow J.E., and Straus S.E. Acyclovir-induced renal failure. Clinical course and histology. Am. J. Med. 84 (1988) 1067-1071
33. Bianchetti M.G., Roduit C., and Oetliker O.H. Acyclovir-induced renal failure: course and risk factors. Pediatr. Nephrol. 5 (1991) 238-239
34. Becker B.N., Fall P., Hall C., Milam D., Leonard J., Glick A., et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am. J. Kidney Dis. 22 (1993) 611-615
35. Fogazzi G.B. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol. Dial. Transplant. 11 (1996) 379-387
36. Daudon M., Protat M.F., and Reveillaud R.J. Triamterene and renal calculi. Nephrologie 3 (1982) 119-123
37. Moesch C., Dumas J.P., and Leroux-Robert C. Urinary lithiasis due to triamterene. Ann. Urol. (Paris) 24 (1990) 17-20
38. Carey R.A., Beg M.M., McNally C.F., and Tannenbaum P. Triamterene and renal lithiasis: a review. Clin. Ther. 6 (1984) 302-309
39. Sorgel F., Ettinger B., and Benet L.Z. The true composition of kidney stones passed during triamterene therapy. J. Urol. 134 (1985) 871-873
40. Carr M.C., Prien Jr. E.L., and Babayan R.K. Triamterene nephrolithiasis: renewed attention is warranted. J. Urol. 144 (1990) 1339-1340
41. Fairley K.F., Birch D.F., and Haines I. Abnormal urinary sediment in patients on triamterene. Lancet 1 (1983) 421-422
42. Kau S.T. Handling of triamterene by the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 206 (1978) 701-709
43. Daudon M., Protat M.F., and Reveillaud R.J. Detection and diagnosis of drug induced lithiasis. Ann. Biol. Clin. (Paris) 41 (1983) 239-249
44. Goadsby P.J., Donaghy A.J., Lloyd A.R., and Wakefield D. Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure. Ann. Intern. Med. 107 (1987) 783-784
45. Diaz F., Collazos J., Mayo J., and Martinez E. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann. Pharmacother. 30 (1996) 41-42
46. Marques L.P., Madeira E.P., and Santos O.R. Renal alterations induced by sulfadiazine therapy in an AIDS patients. Clin. Nephrol. 42 (1994) 68-69
47. Daudon M. Drug-induced urinary calculi in 1999. Prog. Urol. 9 (1999) 1023-1033
48. Albala D.M., Prien Jr. E.L., and Galal H.A. Urolithiasis as a hazard of sulfonamide therapy. J. Endourol. 8 (1994) 401-403
49. Erturk E., Casemento J.B., Guertin K.R., and Kende A.S. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J. Urol. 151 (1994) 1605-1606
50. Joekes A.M., Rose G.A., and Sutor J. Multiple renal silica calculi. BMJ 1 (1973) 146-147
51. th case in the world). Rev. Clin. Esp. 151 (1978) 411-413
52. Augusti M., Mikaelian J.C., Monsaint H., Brin D., and Daudon M. A silica urinary calculus secondary to the absorption of gelopectose in a child. Prog. Urol. 3 (1993) 812-815
53. Reveillaud R.J., Daudon M., Protat M.F., Rymer M., Amar E., and Pottier J. Renal pelvis stones made of glafenic acid in two patients under prolonged treatment with analgesics (author's transl). Nephrologie 1 (1980) 3-8
54. Moesch C., Rince M., Raby C., and Leroux-Robert C. Identification of a metabolite of floctafenine in urinary calculi. Ann. Biol. Clin. (Paris) 45 (1987) 546-550
55. Rince C., Daudon M., Moesch C., Rince M., and Leroux-Robert C. Identification of flumequine in a urinary calculus. J. Clin. Chem. Clin. Biochem. 25 (1987) 313-314
56. Cifuentes I., Bellanato J., Arquillue A., and Lazaro J. Presence of oxolinic acid in a renal calculus. Arch. Esp. Urol. 39 (1986) 369-373
57. Daudon M., Reveilland R.J., Laurence C., and Guenel J. Drug-induced oxolinic acid crystalluria and nephrolithiasis. Clin. Nephrol. 28 (1987) 156
58. Chopra N., Fine P.L., Price B., and Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J. Urol. 164 (2000) 438
59. Nakano M., Ishihara S., Deguchi T., Kuriyama M., and Kawada Y. Fluoroquinolone associated bladder stone. J. Urol. 157 (1997) 946
60. Daudon M., and Estepa L. Drug induced lithiases. Presse Med. 27 (1998) 675-683
61. Cochat P., Cochat N., Jouvenet M., Floret D., Wright C., Martin X., et al. Ceftriaxone-associated nephrolithiasis. Nephrol. Dial. Transplant. 5 (1990) 974-976
62. Mulvaney W.P., Beck C.W., and Brown R.R. Urinary phenazopyridine stones. A complication of therapy. JAMA 221 (1972) 1511-1512
63. Pickens C.L., Milliron A.R., Fussner A.L., Dversdall B.C., Langenstroer P., Ferguson S., et al. Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Urology 54 (1999) 23-27
64. Assimos D.G., Langenstroer P., Leinbach R.F., Mandel N.S., Stern J.M., and Holmes R.P. Guaifenesin- and ephedrine-induced stones. J. Endourol. 13 (1999) 665-667
65. Sand T.E., and Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur. J. Clin. Pharmacol. 19 (1981) 453-456
66. Lehmann D.F. Primidone crystalluria following overdose. A report of a case and an analysis of the literature. Med. Toxicol. Adverse Drug Exp. 2 (1987) 383-387
67. Pak C.Y., Sakhaee K., Hwang T.I., Preminger G.M., and Harvey J.A. Nephrolithiasis from calcium supplementation. J. Urol. 137 (1987) 1212-1213
68. Daudon M., Lacour B., Jungers P., Drueke T., Reveillaud R.J., Chevalier A., et al. Urolithiasis in patients with end stage renal failure. J. Urol. 147 (1992) 977-980
69. Kass M.A., Kolker A.E., Gordon M., Goldberg I., Gieser D.K., Krupin T., et al. Acetazolamide and urolithiasis. Ophthalmology 88 (1981) 261-265
70. Takhar J., and Manchanda R. Nephrolithiasis on topiramate therapy. Can. J. Psychiatry 45 (2000) 491-493
71. Kim Y.G., Kim B., Kim M.K., Chung S.J., Han H.J., Ryu J.A., et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol. Dial. Transplant. 16 (2001) 2303-2309
72. Sidhu H., Hoppe B., Hesse A., Tenbrock K., Bromme S., Rietschel E., et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 352 (1998) 1026-1029
73. McLain D.A., Garriga F.J., and Kantor O.S. Adverse reactions associated with ticrynafen use. JAMA 243 (1980) 763-764
74. Matzkies F. Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients. Fortschr. Med. 96 (1978) 1619-1621
75. Navas P., and Grasset D. Anuria due to bilateral ureteral uric acid lithiasis during a treatment with Amplivix. J. Urol. Nephrol. (Paris) 79 12Pt2 (1973) 466-469